Difference between revisions of "Polycythemia vera classification"

Jump to: navigation, search
 
Line 1: Line 1:
 
__NOTOC__
 
__NOTOC__
 
{{Polycythemia vera}}
 
{{Polycythemia vera}}
{{CMG}} {{AE}}{{MJK}}; {{shyam}}
+
{{CMG}} {{AE}} {{IO}} {{MJK}}; {{shyam}}
 
==Overview==
 
==Overview==
 
Polycythemia vera is a subtype of [[myeloproliferative neoplasm]]. [[Myeloproliferative neoplasm]] may be classified according to the World Health Organization into eight subtypes: [[chronic myelogenous leukemia]], [[chronic neutrophilic leukemia]], [[polycythemia vera]], [[primary myelofibrosis]], [[essential thrombocythemia]], [[chronic eosinophilic leukemia]], [[mastocytosis]], and [[Myeloproliferative neoplasm|myeloproliferative neoplasms]], unclassifiable. The classification of [[polycythemia]] is subdivided into primary polycythemia (which is a clonal process caused by the [[Janus kinase|JAK2]] mutation) and secondary [[polycythemia]] (which is a reactive process due to a state of chronic [[hypoxia]]). There are numerous causes of secondary [[polycythemia]], and most of these causes are cardiopulmonary in origin.
 
Polycythemia vera is a subtype of [[myeloproliferative neoplasm]]. [[Myeloproliferative neoplasm]] may be classified according to the World Health Organization into eight subtypes: [[chronic myelogenous leukemia]], [[chronic neutrophilic leukemia]], [[polycythemia vera]], [[primary myelofibrosis]], [[essential thrombocythemia]], [[chronic eosinophilic leukemia]], [[mastocytosis]], and [[Myeloproliferative neoplasm|myeloproliferative neoplasms]], unclassifiable. The classification of [[polycythemia]] is subdivided into primary polycythemia (which is a clonal process caused by the [[Janus kinase|JAK2]] mutation) and secondary [[polycythemia]] (which is a reactive process due to a state of chronic [[hypoxia]]). There are numerous causes of secondary [[polycythemia]], and most of these causes are cardiopulmonary in origin.

Latest revision as of 01:37, 14 September 2019

Polycythemia vera Microchapters

Home

Patient Information

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Polycythemia vera from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polycythemia vera classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polycythemia vera classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polycythemia vera classification

CDC on Polycythemia vera classification

Polycythemia vera classification in the news

Blogs on Polycythemia vera classification

Directions to Hospitals Treating Polycythemia vera

Risk calculators and risk factors for Polycythemia vera classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ifeoma Odukwe M.D. [2] Mohamad Alkateb, MBBCh [3]; Shyam Patel [4]

Overview

Polycythemia vera is a subtype of myeloproliferative neoplasm. Myeloproliferative neoplasm may be classified according to the World Health Organization into eight subtypes: chronic myelogenous leukemia, chronic neutrophilic leukemia, polycythemia vera, primary myelofibrosis, essential thrombocythemia, chronic eosinophilic leukemia, mastocytosis, and myeloproliferative neoplasms, unclassifiable. The classification of polycythemia is subdivided into primary polycythemia (which is a clonal process caused by the JAK2 mutation) and secondary polycythemia (which is a reactive process due to a state of chronic hypoxia). There are numerous causes of secondary polycythemia, and most of these causes are cardiopulmonary in origin.

Classification

Classification of myeloproliferative neoplasms

Polycythemia vera is a subtype of myeloproliferative neoplasm. Myeloproliferative neoplasm may be classified according to the World Health Organization into eight subtypes:[1][2][3][4][5][6][7][8][9][10]

There are no subcategories within polycythemia vera.

Classification of polycythemia

Polycythemia vera is a subcategory of polycythemia in general. Classification of polycythemia in general includes primary polycythemia and secondary polycythemia. Secondary polycythemia is due to chronic hypoxia which results in compensatory increase in erythrocyte production. Secondary polycythemia is therefore characterized by a reactive increase in erythrocyte production, rather than clonal proliferation of erythrocytes.

References

  1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A; et al. (2009). "The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes". Blood. 114 (5): 937–51. doi:10.1182/blood-2009-03-209262. PMID 19357394.
  2. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB; et al. (2001). "Diagnostic criteria and classification of mastocytosis: a consensus proposal". Leuk Res. 25 (7): 603–25. PMID 11377686.
  3. Birgegård G (2015). "Advances and challenges in the management of essential thrombocythemia". Ther Adv Hematol. 6 (3): 142–56. doi:10.1177/2040620715580068. PMC 4480522. PMID 26137205.
  4. Beatrice JM, Garanito MP (2013). "Essential thrombocythemia: a rare disease in childhood". Rev Bras Hematol Hemoter. 35 (4): 287–9. doi:10.5581/1516-8484.20130059. PMC 3789436. PMID 24106449.
  5. Hayashi Y, Hirai H, Kamio N, Yao H, Yoshioka S, Miura Y; et al. (2013). "C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion". Leukemia. 27 (3): 619–28. doi:10.1038/leu.2012.258. PMC 4506742. PMID 22948537.
  6. Gotlib J (2017). "How I treat atypical chronic myeloid leukemia". Blood. 129 (7): 838–845. doi:10.1182/blood-2016-08-693630. PMID 27899359.
  7. Maxson JE, Tyner JW (February 2017). "Genomics of chronic neutrophilic leukemia". Blood. 129 (6): 715–722. doi:10.1182/blood-2016-10-695981. PMC 5301820. PMID 28028025.
  8. Desterke C, Martinaud C, Ruzehaji N, Le Bousse-Kerdilès MC (2015). "Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis". Mediators Inflamm. 2015: 415024. doi:10.1155/2015/415024. PMC 4660030. PMID 26640324.
  9. Vidyadharan S, Joseph B, Nair SP (2016). "Chronic Eosinophilic Leukemia Presenting Predominantly with Cutaneous Manifestations". Indian J Dermatol. 61 (4): 437–9. doi:10.4103/0019-5154.185716. PMC 4966405. PMID 27512192.
  10. Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O; et al. (2017). "Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future". Cancer Res. 77 (6): 1261–1270. doi:10.1158/0008-5472.CAN-16-2234. PMC 5354959. PMID 28254862.

Linked-in.jpg